|
|
|
|
Vol. 9, Issue 7, 1695-1708, July 1998

Department of Neurobiology, ¶Program in Neuroscience, Harvard Medical School, Boston, Massachusetts 02115
Submitted November 24, 1997; Accepted April 17, 1998| |
ABSTRACT |
|---|
|
|
|---|
Association of mRNA with the cytoskeleton represents a fundamental aspect of RNA physiology likely involved in mRNA transport, anchoring, translation, and turnover. We report the initial characterization of a protein complex that binds RNA in a sequence-independent but size-dependent manner in vitro. The complex includes a ~160-kDa protein that is bound directly to mRNA and that appears to be either identical or highly related to a ~1600-kDa protein that binds directly to mRNA in vivo. In addition, the microtubule-associated protein, MAP 1A, a cytoskeletal associated protein is a component of this complex. We suggest that the general attachment of mRNA to the cytoskeleton may be mediated, in part, through the formation of this ribonucleoprotein complex.
| |
INTRODUCTION |
|---|
|
|
|---|
The cytoskeletal network plays important roles in the maintenance
of cell shape and the transport and anchoring of cellular components. A
less appreciated role of the cytoskeleton is its function as a physical
anchor and transport substrate for the key mediators of gene expression
in the cytoplasm
the mRNA molecules. Evidence in several experimental
systems has shown this interaction to be critical for the spatial and
temporal regulation of protein synthesis.
The first direct demonstration that cellular mRNAs are not free to
diffuse in the cytoplasm but, rather, are attached to the cytoskeleton,
was provided by experiments carried out by Penman and co-workers. They
observed that actively translating polyribosomes are associated with
the cellular cytoskeleton (Lenk et al., 1977
; Cervera
et al., 1981
; Ornelles et al., 1986
). Subsequent
studies confirmed these initial findings and demonstrated that isolated cytoskeletons from a variety of different cell types retained translational components including polyribosomes, translation factors,
and mRNA (see Pachter [1992] for a review). Indeed, for the vast
majority of mRNA species analyzed to date, 75-95% of the population
has been found to be associated with the cytoskeleton (Pachter, 1992
).
In addition to mRNA on polyribosomes, RNAs that are not associated with
ribosomes, such as untranslated messenger ribonucleoprotein particles
(mRNPs), have also been shown to be attached to the cytoskeleton in
some experimental systems (Bird and Sells, 1986
). Furthermore, when
mRNAs are dissociated from ribosomes, the RNAs still remain associated
with the cytoskeleton, indicating a direct attachment that is
independent of ribosomes (Lenk et al., 1977
; Howe and
Hershey, 1984
). When exogenous RNAs are introduced into the cell, for
instance after viral infections, they too have been found to associate
with the cytoskeleton (Ben-Ze'ev et al., 1981
; Bonneau
et al., 1985
; Jones and Kilpatrick, 1988
).
mRNA attachment to the cytoskeleton has been shown to be involved in
several aspects of mRNA regulation. There is evidence to suggest that
cytoskeletal interactions are required for mRNA localization (e.g.,
Pondel and King, 1988
; Yisraeli et al., 1990
; Sundell and
Singer, 1991
; Ainger et al., 1993
; Ferrandon et
al., 1994
; Pokrywka and Stephenson, 1995
; Olink-Coux and
Hollenbeck, 1996
). In addition, it has been shown in several
experimental systems that one of the requirements for translation is
the attachment of RNA to the cytoskeleton. For example, in certain
virus-infected cells, the replacement of host protein synthesis by
viral protein synthesis is accompanied by the displacement of host RNAs
from the cytoskeleton and their replacement by viral RNAs (Lenk and Penman, 1979
; Van Venrooij et al., 1981
). In sea urchin
oocytes, the stored maternal mRNAs appear to become attached to the
cytoskeleton only when they become activated for translation (Moon
et al., 1983
). It is possible that the structure provided by
the cytoskeleton allows translational components and RNA to reside in
close proximity, thereby increasing efficiency of translation
(Negrutskii et al., 1994
).
Here we describe a general cytoplasmic protein complex that binds RNA and contains at least one cytoskeleton-associated protein. Using UV cross-linking we first identified a ~160-kDa protein directly bound to mRNA in vivo. Then, by electrophoretic mobility shift assays and UV cross-linking experiments in vitro, we found that a very similar, potentially identical, ~160-kDa protein is a component of a protein complex that binds RNA in a sequence-independent but size-dependent manner. In addition to the ~160-kDa protein, this ribo-protein complex contains the microtubule-associated protein, MAP 1A.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Cell Culture and Drug Treatment
PC12 cells were grown in DMEM (GIBCO-BRL, Gaithersburg, MD) supplemented with 10% horse serum, 5% FCS, L-glutamine (0.3 mg/ml), and penicillin/streptomycin (100 U penicillin G and 100 µg streptomycin/ml) in 5% CO2, at 37°C. For experiments, 2 × 106 cells were plated on 100-mm poly-L-lysine-coated plates. In most experiments, cells were treated with 100 ng/ml of nerve growth factor (NGF) (Promega, Madison, WI) for 16 h. Where indicated, cells were treated with NGF for 7 d. In these cases, 2 × 105 cells were plated per dish, and media and NGF were replaced twice during this period.
In some experiments, cells were treated for 1 h with puromycin (Sigma Chemical, St. Louis, MO) at 12.5 µg/ml. The effectiveness of the drug treatment was determined by incubating control and puromycin-treated cells with 35S-methionine (600 µCi/ml) (New England Nuclear, Boston, MA) for 45 min, followed by two washes with PBS. The cells were then lysed by replacing the media with 150 mM NaCl, 1% NP-40, 50 mM Tris-HCl, pH 8, at 4°C for 30 min with gentle shaking. The lysates were centrifuged at 12,000 × g for 10 min at 4°C, and aliquots from each supernatant were diluted 1:50 with 1 M NaOH/2% H2O2. The samples were then vortexed and incubated at 37°C for 10 min. To precipitate proteins, samples were diluted 1:5 with 25% trichloroacetic acid (TCA)/2% casamino acids and incubated at 4°C for 30 min. The samples were then vacuum filtered onto glass fiber filters, washed extensively with cold, 5% TCA, and given a final wash with acetone. Dried filters were counted in a scintillation counter.
In Vivo UV Cross-linking of RNA to Proteins
In vivo UV cross-linking was carried out essentially as
described in Piñol-Roma et al., 1989
. PC12 cells were
plated in 100 mm tissue culture dishes and then treated with 100 ng/ml
NGF in DMEM for 16 h. The media was removed and replaced with DMEM
containing 100 ng/ml NGF and 3H-uridine at a final
concentration of 175 µCi/ml [5,6-3H]-uridine, 40 Ci/mmol; NEN, Boston, MA) for 3 h at 37°C. Puromycin was then
added to a final concentration of 200 µg/ml and incubated for an
additional 30 min at 37°C. The plates were washed twice with PBS. PBS
(2 ml) was added to the plates, and the plates were placed at a
distance of 2.5 cm from a germicidal UV light (intensity 2200 µW/cm2) for 7 min. Protease inhibitors were added to all
buffer solutions at the following concentrations: 10 mM
aminoethylbenzenesulfonylfluoride (Calbiochem, San Diego, CA), 10 mM
leupeptin (Sigma), 10 mM aprotinin, 1 mM pepstatin in addition to
2.5-3 U RNAse inhibitor Inhibit-ACE (5 Prime
3 Prime, Boulder,
CO). The cells were hypotonically lysed and homogenized by passing them
four times through a 26-gauge needle. The nuclei were pelleted and the
supernatant was heated to 65°C for 10 min and then adjusted to 1%
-mercaptoethanol, 10 mM EDTA, and 0.5 M LiCl for binding to the
oligo dT cellulose. After binding at room temperature for 45 min with
gentle agitation, the oligo dT was washed twice with binding buffer (10 mM Tris, pH 7.5, 1 mM EDTA, 0.5 M LiCl, and 0.5% SDS). The poly
A+ RNA along with its covalently linked RNA-binding
proteins were eluted from the oligo dT cellulose by washing twice with
low-salt elution buffer (10 mM Tris, pH 7.5, 1 mM EDTA, and 0.5% SDS)
containing RNAse A (final concentration of 300 µg/ml) and RNAse T1
(final concentration of 10 U/ml) for 1 h at room temperature. The
eluted samples were concentrated using a Centricon 30 microconcentrator (Amicon, Beverly, MA) and then analyzed on a 10% SDS polyacrylamide gel. After electrophoresis, the gels were treated with EN
3HANCE (New England Nuclear, Boston, MA), dried, and
visualized by fluorography.
Preparation of Binding Extracts
PC12 and COS-7 cells were plated and grown 16 h before
harvesting. PC12 cells were treated with 100 ng/ml NGF during the
16 h of growth. Tissues were handled in essentially the same
manner as the PC12 and COS-7 cells with the exception that the tissues were minced and mechanically homogenized (500 rpm) before cells were
pelleted and incubated in hypotonic lysis buffer. Cytoplasmic extracts
were prepared essentially according to Dignam et al. (1983)
with the exception of an incubation in high-salt (700 mM KCl) buffer
prior to final centrifugation. Protease inhibitors were added to
preparation buffers at the following concentrations: 10 mM
aminoethylbenzenesulfonylfluoride (Calbiochem, San Diego, CA),
10 mM leupeptin (Sigma Chemical), 10 mM aprotinin (Sigma Chemical), 1 mM pepstatin (Sigma Chemical), 0.5 mM EDTA, and 1 mM DTT. Bio-Rad
Protein Assay (Bio-Rad, Hercules, CA) was used to determine the protein
concentration of each lysate.
Preparation of Radiolabeled Probes and Nonradiolabeled Competitor RNA
The full-length GAP-43 cDNA (kindly provided by L. Benowitz) was
used as a template in the PCR to generate DNA fragments that encompass
various regions of the rat GAP-43 mRNA. Primers contained sequences for
either an ApaI or NsiI restriction site to
facilitate cloning into the RNA synthesis vector, pGEM 7 (Promega,
Madison, WI). The GAP-43 sequence numbers that define the DNA region of interest are as follows (numbering according to (Basi et
al., 1987
): GAP A, 708-839, GAP B, 868-1000, and GAP C,
1023-1152. Due to errors in the PCR, there was a loss of 21 nucleotides (nt) near the 3'-end of the GAP C fragment. pGEM 7 plasmids
containing either GAP A, GAP B, or GAP C DNA fragments were linearized
with ApaI, and RNA was synthesized with SP6 RNA polymerase
in the presence of 32P-UTP (final specific activity, 27 Ci/mmol). Because there are 20 nt of vector sequence that contribute to
each RNA probe synthesized, the length of the GAP A probe is 152 nt
while the GAP B probe length is 153 nt and the GAP C probe length is
129 nt. Antisense probes were generated by linearizing the plasmids
with NsiI and using T7 RNA polymerase for RNA synthesis.
For preparation of the gap a, gap b, and gap c probes, complementary oligomers representing the sense or antisense strands of different regions of the rat GAP-43 cDNA were hybridized and the double-stranded DNA fragments were cloned into pGEM 7. The gap a, gap b, and gap c regions span sequence numbers 748-775, 881-908, and 1051-1078, respectively. Because there are 20 nt of vector sequence and 6 nt of an added restriction site, when the gap a, gap b, and gap c RNA probes are synthesized, the lengths are each 54 nt.
After RNA synthesis the reaction is electrophoresed on a 6% urea polyacrylamide gel, visualized by autoradiography, and the band containing the RNA excised from the gel. The RNA is eluted from the gel slice by incubating either 4 h at 37°C or overnight at room temperature in 0.5 M ammonium acetate in diethylpyrocarbonate-treated water, pH 7.5. After centrifugation, the supernatant is removed, ammonium acetate is added to a final concentration of 2 M, and the supernatant is precipitated with 2.5 volumes of ethanol. The precipitated RNA is resuspended in diethylpyrocarbonate-treated water and an aliquot quantitated by liquid scintillation counting.
Competitor RNAs were synthesized from the same vectors as the 32P-radiolabeled probes. RNA is radiolabeled for quantification by including trace amounts of 3H-UTP (final specific activity, 17.5 mCi/mmol) in the RNA synthesis reaction. The competitor RNAs are gel purified as the 32P-radiolabeled probes (above) with the exception that visualization after PAGE is achieved by UV shadowing against an autoradiographic intensifying screen instead of autoradiography.
Binding Reaction and Mobility Shift Assays
Radiolabeled RNA (50,000 dpm) (~240 pg of the 120- to 150-nt
probes and 81 pg of the 50-nt probes) was heated to 95°C for 4 min
and then cooled on ice for at least 3 min. The denatured RNA was then
added to 1 µg PC12 cell extract or 10 µg tissue extract in 9 µl
of 10 mM Tris, pH 7.5, 5% glycerol, 1 mM EDTA, 100 mM KCl (or greater
KCl concentration when testing complex stability), and 1 mM DTT in a
final volume of 10 µl. The radiolabeled RNA and proteins were
incubated at room temperature for 30 min. After 50 µg of heparin were
added, the incubation was continued for 10 min, and 0.5 µl of 0.1%
bromophenol blue was then added. The reaction was loaded on a 6%
nondenaturing polyacrylamide gel (28.2:0.8) in 0.5× TBE (1× TBE = 89 mM Tris, 8.9 mM borate, 2 mM EDTA, pH 8.3), which had been prerun
overnight at 50 V and electrophoresed at 200 V for 3.5 h. The gel
was dried and then visualized by autoradiography. In competition
experiments 5 × 10
15 mol RNA probe (50,000-80,000
dpm of 120- to 150-nt probes or 12,000-25,000 dpm for 50-nt probes)
was used and processed as described above.
Binding Reaction for Competition Assays
Binding reactions for competition assays were performed as described with the exception that the tissue extract was preincubated at room temperature for 15 min with the nonradiolabeled competitor RNA before the radiolabeled probe was added to the reaction. The random RNA polymers polyadenylic-guanylic-uridylic acid (~300 nt average length) and polycytidylic-inosinic-uridylic acid (~300 nt average length) (Sigma) were used as the single-stranded competitors and polyadenylic-polyuridilic acid (~900 bp average length) and polycytidylic-polyguanylic acid (~240 bp average length) (Sigma) were used as the double-stranded competitors. Single stranded calf thymus DNA (Sigma) (~700 nt average length) was used as the DNA competitior.
Binding Reaction for Supershift Assays
The supershift assay was performed essentially as described
above with the following additions: 0.5 U of the RNAse inhibitor Inhibit-ACE (5 Prime
3 Prime, Boulder, CO) and antibodies, with the
exception of antibody clone MAP1A1, were added to the protein extract
and allowed to incubate for 15 min on ice before the addition of the
radiolabeled probe. The antibody clone MAP1A1 was incubated with the
extract for 15 min on ice after the binding reaction and before the
addition of heparin. Antibodies were added in two different forms: all
were tested as ascites fluid at a dilution of 1:25, and some were also
tested using 1.5 µg of the IgG fraction isolated from ascites fluid.
Antibodies
The ascites fluids used were as follows: MAP-1A (clone HM-1,
Chemicon International, Temecula, CA), MAP 1A (clone 1A1, gift from G. Bloom and R. Vallee); MAP-2 (clone HM-2, Sigma), and MAP-1B (clone 3G5,
Chemicon International), actin (clone C4, Chemicon International), and
-tubulin (clone TUB 2.1, Sigma). When used, the IgG fraction was
isolated from ascites fluid using the E-Z-SEP IgG Partitioning Reagents
(Pharmacia, Uppsala, Sweden).
In Situ UV Cross-linking and Two-Dimensional Electrophoresis
UV cross-linking was carried out essentially as described by
Garcia-Blanco et al. (1989)
. After the RNA-protein binding
reaction was subjected to nondenaturing PAGE as described above, the
wet polyacrylamide gel was placed on ice at a distance of 8 cm from a
germicidal UV light (intensity 2200 µW/cm2) for 20 min.
After UV cross-linking, the polyacrylamide gel was wrapped in Saran
wrap and visualized by autoradiography at 4°C overnight. The lane
containing the RNA-protein complexes was excised, placed in a tube
with TE (10 mM Tris, pH 8, and 1 mM EDTA) containing 330 µg/ml RNAse
A and 50 U/ml RNAse T1 and incubated at 37°C for 1 h. The RNase
solution was removed, and the gel slice was incubated with 2 × SDS PAGE buffer at 37°C for 1 h and subsequently at 65°C for
15 min. The gel slice was embedded into the stacking portion (6 cm) of
a 10% SDS-polyacrylamide gel (17 cm separating) by layering low
melting temperature agarose below and above the gel slice to facilitate
the embedding.
Electroelution of Complex 1 Protein Components
Complex 1 was excised from a UV cross-linked nondenaturing polyacrylamide gel as described above. The gel slice was placed into the Hoefer GE 200 SixPac Gel Eluter (Hoefer, San Francisco, CA), and the proteins were eluted by applying 50 V for 200 min. The eluate was treated for 30 min at room temperature with Rnase A and RNase T1 at concentrations of 100 µg/ml and 50 U/ml, respectively. The proteins were precipitated in the presence of 25 µg/ml BSA carrier protein by addition of TCA to a final concentration of 5%. The precipitate was washed, resuspended in 1× Laemmli loading buffer and analyzed by SDS-PAGE.
Peptide Analysis of the in Vitro Identified ~160-kDa RNA-Binding Protein
Radiolabeled GAP A (2 × 106 dpm) was incubated
with 375 µg of brain extract, electrophoresed through a nondenaturing
polyacrylamide gel, UV cross-linked, and visualized as described above.
The region of complex 1 was excised, treated with RNase, and
equilibrated in SDS loading buffer as above. After electrophoresis
through a 10% denaturing polyacrylamide gel, the region containing
160-kDa proteins was excised, and the slice was equilibrated in
denaturing buffer as described by Cleveland et al. (1977)
.
The slice was embedded into the stacking portion (6 cm) of a 15% SDS
polyacrylamide gel (17 cm separating) by layering
low-melting-temperature agarose in the well below the slice, to
facilitate embedding. Digestion was carried out essentially as
described by Cleveland et al. (1977)
. Briefly, the gel slice
was overlayed with 50 µg of Staphylococcus aureus V8
protease (Sigma) in 20 µl 0.125 M Tris, pH 6.8, 0.1% SDS, 1 mM EDTA,
20% glycerol, and 0.005% bromophenol blue. Electrophoresis proceeded
until the bromophenol blue was within the last centimeter of the
stacking gel. At that time, the power was turned off for 45 min, after
which electrophoresis continued until the bromophenol blue was near the
bottom of the separating gel.
Peptide Analysis of the in Vivo Identified ~160-kDa mRNA-binding Protein
In vivo cross-linking of PC12 cells was carried out as described
above. After electrophoresis, the region containing 160-kDa proteins
was excised and the gel slice was equilibrated in denaturing buffer as
described by Cleveland et al. (1977)
. The slice was subsequently processed and digested with S. aureus V8
protease as described above for the in vitro peptide analysis.
| |
RESULTS |
|---|
|
|
|---|
In Vivo Evidence for a ~160-kDa mRNA-binding Protein
To identify general RNA-protein interactions in the cytoplasm,
PC12 cells were radiolabeled with tritiated uridine and exposed to UV
light to cross-link all of the cellular RNAs to the proteins with which
they are interacting in the living cell. A number of proteins, both
nuclear and cytoplasmic, have been previously shown to be complexed
with mRNA in vivo by means of such UV cross-linking (Piñol-Roma
et al., 1989
). To exclude RNA-protein interactions related
to protein synthesis, the cells were first treated with a concentration
of puromycin that inhibited translation by 97%, as assessed by
incorporation of 35S-methionine (our unpublished
observations; see MATERIALS AND METHODS). The cells were then exposed
to UV light to cross-link the cellular RNAs to their associated
proteins. Oligo-dT cellulose was used to isolate total poly
A+ RNA along with its cross-linked proteins from the cells.
After binding the oligo dT cellulose, the proteins that were covalently linked to the poly A+ RNA were recovered by low-salt
and RNAse A and RNAse T1 treatment. The released proteins, along with
the few remaining covalently linked radionucleotides, were then
subjected to SDS-PAGE and detected by fluorography. Several
radiolabeled proteins, including an approximately 160-kDa species, were
observed (Figure 1).
|
The ~160-kDa RNA-binding Protein Detected in Vivo Is, or Is Closely Related to, a Component of a Protein Complex That Binds RNA in a Sequence-insensitive, Size-dependent Manner in Vitro
Due to the nature of the in vivo cross-linking method, the mRNA-protein interactions it identifies most likely represent the average of frequent events that involve most mRNA molecules in the cell. To further examine these general RNA-protein interactions, studies were carried out to identify and characterize RNA-protein interactions in an in vitro system. The electrophoretic mobility shift assay (EMSA) has been used extensively to detect the association of nucleic acids and proteins. Here EMSA was used to analyze the interaction of protein extracts and in vitro-synthesized RNA as a means of probing the nt sequence-independent association of proteins with mRNA.
Sequence Independence Protein extracts were incubated with several in vitro-synthesized, radiolabeled RNAs and analyzed by EMSA. In initial experiments we used NGF-treated PC12 cell extracts and three RNA species as probes, GAP A, GAP B, and GAP C, each encoding approximately equal portions of the 3'-untranslated region (UTR) of the GAP-43 mRNA (Figure 2A) and sharing very low levels of homology with each other. The PC12 cell protein extract contained proteins that bound each RNA and gave rise to distinct RNA-protein complexes (Figure 2B). At least one common, comigrating complex was formed independently of the RNA probe used. This common complex is the largest (least mobile) detected and will be subsequently referred to as complex 1. The generation of seemingly identical comigrating complex 1 bands using different RNAs was indicative of a general sequence-independent RNA-protein interaction. Protein extracts from brain were then also tested for their ability to interact with the different RNA species. As with PC12 cell extracts, we observed that the brain extract could form complex 1 with GAP A, GAP B, or GAP C probes (Figure 2C). Indeed, in all subsequent experiments, brain extract and PC12 cell extract behaved in an essentially identical manner.
|
|
Size Dependence. The RNA species tested thus far in the mobility shift assays were at least 120 nt in length and were all capable of forming complex 1. To investigate the size requirement for complex 1 formation, we constructed RNA probes that were 54 nt in length and represented a subset of the larger GAP A, GAP B, and GAP C probes. Their ability to interact with brain protein extract was determined by EMSA as previously described. Use of the shorter probes, denoted gap a, gap b, and gap c, respectively (Figure 2A), resulted in the formation of RNA-protein complexes that did not comigrate with complex 1 (Figure 3C). These and results with other various sized probes (our unpublished results) indicate that the formation of complex 1 is dependent on a minimum length of RNA of approximately 120 nt.
To explore the possibility that some protein component(s) of complex 1 is (are) also included in the RNA-protein species detected by mobility shift assay using the (shorter) gap a, gap b, or gap c probes, competition experiments were performed. Nonradiolabeled gap a, gap b, or gap c was added to binding reactions of radiolabeled GAP A, GAP B, or GAP C probes and brain extract. Although gap a, gap b, and gap c do not form complex 1, each species was able to interfere with the formation of complex 1 and other complexes formed by RNA-protein interactions with the larger probes (Figure 3D). Although there were slight differences in the ability of each of the shorter gap probes to compete with the radiolabeled GAP A, GAP B, or GAP C probes for protein binding, none were as effective as the GAP A, GAP B, or GAP C competitors themselves (Figure 3A). These findings indicate that while the smaller RNAs cannot interact with the extract proteins to form complex 1, they are capable of binding at least one component found in the brain extracts that is necessary for complex 1 formation.A ~160-kDa Protein Is Found in Complex 1 by in Vitro UV
Cross-linking.
If complex 1 represents a nt sequence-independent
RNA-protein interaction that occurs in vivo, its RNA-binding
component(s) should be similar to those found complexed to mRNA in
vivo. To address this question, the protein(s) comprising complex 1 were further characterized in experiments employing in situ
cross-linking and two-dimensional gel electrophoresis. After the
RNA-protein binding reaction and electrophoresis for mobility shift
detection, the nondenaturing polyacrylamide gel was exposed to UV light
to covalently cross-link the radiolabeled RNA to proteins at sites of
direct RNA-protein contact. This procedure, in effect, transfers the
radiolabeled nt of the RNA to the protein. The lane from the nondenaturing polyacrylamide gel was then excised, treated with RNase
to trim all but the short stretch of nt that are cross-linked to, or
protected by, the protein, and layered onto a SDS-polyacrylamide gel
for electrophoresis in the second dimension (Garcia-Blanco et
al., 1989
). After electrophoresis and detection by
autoradiography, the size of the protein(s) bound directly to the
radiolabeled RNA could be estimated (mass determination will be
approximate because migration of the RNA-binding proteins will be
slightly affected by the presence of the cross-linked oligonucleotide
fragment). Such in situ cross-linking of complex 1 formed with either
the GAP A, GAP B, or GAP C probes and the protein extract revealed a
major radiolabeled protein species of approximately 160 kDa (Figure
4A). The size of this RNA-binding protein
is identical to that of one of the proteins detected by the in vivo
cross-linking of RNA described earlier (Figure 1).
|
V8 Protease Digestion Indicates That the ~160-kDa mRNA-binding
Protein Observed in Vivo Is Highly Similar to the ~160-kDa Protein
Identified in Vitro.
Thus far, two RNA-binding proteins have been
described: a ~160-kDa protein that interacts with RNA in a
sequence-independent, size-dependent manner in vitro, and a ~160-kDa
protein that cross-links to the majority of poly A+ RNA in
vivo. To determine whether these general RNA-binding proteins were
related, we cross-linked proteins to radiolabeled RNA both in vivo and
in vitro and compared their radiolabeled peptide profiles after
digestion by S. aureus V8 protease. For analysis of the RNA-binding protein found in vitro, EMSA was performed using the protein extract and the 32P-radiolabelled GAP A probe.
After UV cross-linking and autoradiographic visualization, complex 1 was excised from the nondenaturing polyacrylamide gel, treated with
RNAse A and RNAse T1, and electrophoresed on a denaturing
polyacrylamide gel as described above. The region of the ~160-kDa
protein was then excised and layered onto the stacking gel of a
denaturing polyacrylamide gel along with S. aureus V8
protease. Digestion by S. aureus V8 protease occurred in
situ during a pause in electrophoresis through the stacking gel
(Cleveland et al., 1977
). Two major radiolabeled peptide
fragment species, approximately ~7 kDa and ~9 kDa, remained after
digestion (Figure 5).
|
The RNA-binding Complex 1 Includes the Cytoskeletal Associated Protein MAP 1A
The sequence-independent nature of RNA binding by the ~160-kDa
protein of complex 1 and its apparently general association to mRNA in
vivo is consistent with the possibility that it is involved in binding
mRNA to the cytoskeleton. To test this possibility, the presence of
cytoskeletal components in the in vitro-formed complex 1 was monitored
using the "supershift" assay. In this assay antibodies to possible
protein components of the RNA-protein complex are included in the
reaction mixture containing the protein extract and the RNA probe. If
the antibody binds a component of a complex, complex formation can be
inhibited or the migration of the resultant complex can be retarded
(supershifted) as compared with the original complex detected in
standard EMSA. Among a number of antibodies directed toward
cytoskeletal elements, only antibodies to MAP 1A (HM1 clone) (Huber and
Matus, 1984
) decreased the mobility of, or supershifted, complex 1 (Figure 6A). MAP 1A, whose function remains unknown, is one of the major proteins found associated with
microtubules and is widely distributed among different cell types
(Bloom et al., 1984
; Wiche et al., 1984
). A
second antibody to MAP 1A (MAP 1 A1 clone) (Bloom et al.,
1984
) was capable of disrupting complex 1, strengthening the conclusion
that complex 1 contains MAP 1A, rather than an unknown MAP 1A
cross-reacting species (our unpublished results). Complex 1 was neither
supershifted nor disrupted with antibodies to MAP 2,
-actin,
-tubulin, tau, or cytoplasmic dynein (Figure 6A). In all cases the
antibody added to the probe alone had no effect on its mobility. These
results suggest that MAP 1A is a component of a protein complex that
binds to single-stranded RNA in a sequence-independent but
size-dependent manner.
|
To determine whether MAP 1A was a general component of complex 1 formed with different RNA probes, we tested the ability of complex 1 formed with GAP B, GAP C, antisense GAP A, and antisense GAP C probes to interact with antibodies to MAP 1A. As with GAP A, the complex 1 formed with each of the different RNA probes was supershifted by the MAP 1A antibodies (Figure 6B). Moreover, the addition of the MAP 1A antibodies often resulted in the stabilization of complex 1 as indicated by the increase in intensity of the supershifted band as compared with the original complex 1 band. MAP 1A antibodies did not affect the migration of any of the complexes formed with gap a, gap b, or gap c probes, indicating the specificity of the complex 1-anti-MAP 1A interaction (Figure 6B). Evidently, only complex 1, capable of forming only with longer RNA probes, includes the cytoskeletal element MAP 1A.
| |
DISCUSSION |
|---|
|
|
|---|
The close association of mRNA with the cytoskeleton of eukaryotic
cells has been a recurring and increasingly convincing finding in a
number of experimental systems. The full physiological significance of
the general association of mRNA with the cytoskeleton is not yet known,
but there is evidence to suggest that cytoskeletal interactions are
important for expression of mRNA, including control of its translation
and its directed movement within the cell. In many cell types (Wilhelm
and Vale, 1993
) including neurons (Chicurel and Harris, 1992
; Steward
and Banker, 1992
; Chicurel et al., 1993
) localization of
mRNA to specific subcellular compartments is a potentially important
regulatory step in the synthesis of proteins (for review see Steward,
1994
, and St Johnston, 1995
).
The cytoplasm is a viscoelastic gel network that acts as a barrier to
the free diffusion of macromolecules (Luby-Phelps, 1993
). However, the
cytoskeletal network provides both a railroad and a scaffold on which
RNA can be efficiently translocated and anchored within the cell. To
facilitate movement along the cytoskeleton and perhaps regulate its
expression, it is likely that RNA is packaged into compact particles.
Interestingly, transported mRNAs have been microscopically visualized
as particles that represent either ribonucleoprotein complexes or
vesicles (Ainger et al., 1993
; Ferrandon et al.,
1994
; Wang and Hazelrigg, 1994
; Knowles et al., 1996
). The
movement of such mRNA-containing particles is apparently an active
process (Ainger et al., 1993
; Knowles et al.,
1996
).
Since the vast majority of mRNAs are associated with the cytoskeleton,
it seems reasonable that a feature common to all mRNAs is responsible
for the linkage. Thus it has been suggested that the 5'-cap structure
(Zumbe et al., 1982
) or the poly A tail (Taneja et
al., 1992
) may direct the mRNA-cytoskeleton interaction. However, RNAs such as poliovirus that lack a 5'-cap (Bonneau et al.,
1985
) and histone and reovirus RNA that lack a poly A tail (Jeffery et al., 1983
; Bonneau et al., 1985
; Zambetti
et al., 1985
) are also found associated with the
cytoskeleton. This indicates that the cap-binding protein (Filipowicz
et al., 1976
; Sonenberg et al., 1979
) or the poly
A-binding protein (Van Venrooij et al., 1977
) cannot alone
account for binding mRNA to the cytoskeleton. Instead, we considered
that a protein complex that binds RNA in a sequence-independent manner
is a more likely candidate for linking RNA to the cytoskeleton.
Until now, proteins involved in the general attachment of RNA to the cytoskeleton have not been identified. Here we describe a ~160-kDa protein that is bound directly to mRNA in vivo and a similar and possibly identical protein that can bind RNA in vitro. The ~160-kDa protein is present in vitro in an RNA-protein complex that includes the microtubule-binding protein MAP 1A. This RNA-protein complex is resistant to dissociation by high salt, requires a minimum length of single-stranded RNA of approximately 120 nt, and forms in a relatively nt sequence-independent manner. Possible roles of this complex include localizing and anchoring mRNA, packaging mRNA, and regulating mRNA stability or translation.
If the ~160-kDa protein interacts with RNA by binding at many sites
within each mRNA molecule, it would resemble several other proteins and
protein complexes that bind nucleic acids in a sequence-independent manner. In addition to the DNA-binding nucleosome, a similar
RNA-binding particle
the ribonucleosome
has been reported to package
nuclear RNA. These RNP particles have been isolated, analyzed, and
found to be composed of heterogeneous nuclear (hnRNP) proteins (for reviews, see Beyer and Osheim, 1990
; Dreyfuss et al., 1990
).
Thus, in additon to their role in splicing (Gorlach et al.,
1993
), the isolated hnRNP proteins are capable of binding RNA in a
sequence-independent and size-dependent manner, similar to the
cytoplasmic RNA-binding complex that we have identified. It is
therefore possible that in a manner analogous to hnRNP binding to
hnRNA, the ~160-kDa protein may play some role in "packaging"
mRNA in the cytoplasm, a putative "cytosome" (Chicurel et
al., 1996
).
Whether such a cytosome complex is only involved in anchoring the RNA
to the cytoskeleton or may also participate in transport of the RNA is
currently unknown. Indeed, there is at least one example in which
nucleic acid movement requires two different protein complexes to carry
out the separable functions of attachment and movement. Chromosome
translocation along spindle microtubules apparently requires both the
microtubule motor-containing complex, CBF3, and other protein(s) whose
sole function is to attach the chromosomes to the microtubules (Sorger
et al., 1995
).
In addition to their effect on mRNA movement and spatial distribution,
mRNA-cytoskeletal interactions likely play a role in regulating
translation. Evidence suggests that protein synthesis in mammalian
cells occurs in a "channeled pathway," in which many of the
components of the synthetic machinery are spatially restricted, such
that individual components are directly transferred to the translational complex without dissociating into the soluble phase of
the cytoplasm (Negrutskii et al., 1994
). In accordance with these findings, a number of proteins that are involved in translational regulation, including the cap-binding protein (Zumbe et al.,
1982
), translation initiation factors eIF-2, eIF3, eIF4A, and eIF-5
(Howe and Hershey, 1984
; Gavrilova et al., 1987
; Heuijerjans
et al., 1989
), and elongation factors eEF1
(Yang et
al., 1990
) and eEF1-2 (Gavrilova et al., 1987
) have
been found associated with the cytoskeleton. Other proteins involved in
posttranscriptional regulation such as poly A+-binding
protein (Greenberg, 1980
) and seryl-tRNA synthetase (Miseta et
al., 1991
) can be found UV cross-linked to the mRNA in vivo. The
RNA-protein complex 1 described here, which includes components that
bind mRNA directly and others that are associated with the cytoskeleton, may similarly participate in the regulation of
translation.
Our finding of an in vitro interaction between a MAP 1A-containing
protein complex and RNA would seem to implicate the microtubule network
as the cytoskeletal system to which the RNA is attached. Interestingly,
in the dendrites of neuronal cells, mRNA is preferentially found
between, rather than on, microtubules (Bassell et al.,
1994
), as is MAP 1A (Shiomura and Hirokawa, 1987
). This is consistent with our findings of the association of mRNA with the
microtubule-associated protein MAP 1A which, as a microtubule
cross-linker, would be found between microtubules. However, there is
evidence indicating that MAP 1A is not exclusively associated with
microtubules but may also be associated with other, as yet
unidentified, intracellular structures (Asai et al., 1985
;
Herrmann and Wiche, 1987
; Fujii et al., 1993
). Thus, complex
1 may mediate attachment of RNA to microtubules, and/or other filament
systems. Indeed, in other experiments, microfilaments (e.g., Ornelles
et al., 1986
; Yisraeli et al., 1990
; Taneja
et al., 1992
), intermediate filaments (e.g., Pondel and
King, 1988
), and microtubules (e.g., Raff et al., 1990
; Yisraeli et al., 1990
; Ainger et al., 1993
;
Ferrandon et al., 1994
; Litman et al., 1994
;
Pokrywka and Stephenson, 1995
; Olink-Coux and Hollenbeck, 1996
) have
all been implicated in the association of mRNA with the cytoskeleton.
Interestingly, while this manuscriprt was being reviewed, MAP 1A light
chain 3 was reported to bind to an AU-rich region in the fibronectin
mRNA 3'-UTR, and to enhance its translation (Zhou et al.,
1997
), further implicating this protein in mRNA physiology.
Taken together, our data suggest that RNA associates with the cytoskeleton through a protein complex that includes MAP 1A and a ~160-kDa protein that binds directly to RNA. The general association of mRNA with the cytoskeleton may play an important role in controlling mRNA expression by regulating more specific interactions, such as those involved in transport or translational control.
| |
ACKNOWLEDGMENTS |
|---|
We would like to thank D. Ginty for helpful discussion. We also thank G. Bloom and R. Vallee for the MAP 1A1 antibody clone. This work was supported by National Institutes of Health grants AG-09665 and AG-08084 (to H.P.). C.D. was supported by National Research Service Award grant CA-0880 and the Freudenberger family. M.E.C. was a Howard Hughes Predoctoral fellow during the completion of part of this work.
| |
FOOTNOTES |
|---|
Present addresses:
Vertex Pharmaceuticals, 130 Waverly St., Cambridge, Massachusetts 02139-4242;
¶Department of Surgical Research, Children's Hospital,
300 Longwood Avenue, Boston, MA 02115.
| |
REFERENCES |
|---|
|
|
|---|
with the cytoskeleton in cells lacking vimentin.
Exp. Cell Res.
181, 317-330[Medline].
.
J. Biol Chem.
266, 19158-19161
.
Nature
347, 494-496[Medline].